VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV...
Read More
VIENNA — Twenty-four weeks of treatment with Harvoni yielded a 12-week sustained virologic response...
UT Health Science Center San Antonio doctor presents results of daclatasvir regimen SAN ANTONIO...
Merck & Co. said Friday that its experimental drug combination for treating chronic hepatitis...
A number of new, highly effective oral treatments for various types of hepatitis C...
Boston—Can treatment of hepatitis C infection with new direct-acting antivirals (DAAs) be shortened to...
Following this program, participants should be better able to: Use in a clinical setting important...
In a phase 2a clinical trial, treatment with beclabuvir and a combination of pegylated...
Multidrug Regimen Seen Challenging Recently Approved Drugs from Gilead Sciences U.S. regulators on Friday...
– In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C...